Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classificação em ações #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Preço da ação
$0.25974701
Última sincronização: 2025-01-06
Valor de mercado
$2.04M
Variação (1 dia)
0.74%
Variação (1 ano)
0.00%
País
FR
Negociar Acticor Biotech SAS (ALACT)

Categoria

EPS de Acticor Biotech SAS (ALACT)
EPS em June 2024 TTM: $-1.95
De acordo com os últimos relatórios financeiros e o preço das ações da Acticor Biotech SAS, o EPS atual da empresa (TTM) é $-1.95. No final de 2022, a empresa teve um EPS de $-1.62, uma diminuição em relação a ao EPS de 2021, que foi de $-1.84.
Histórico de EPS da Acticor Biotech SAS de 2010 até 2026
EPS no final de cada ano
Ano EPS Alterar
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH